title: Ustekinumab for psoriasis and psoriatic arthritis.
abstract: Ustekinumab, which is approved for the treatment of moderate to severe psoriasis, has been shown in phase II clinical trials to be efficacious in controlling the signs and symptoms of psoriatic arthritis. Ustekinumab appears to be well tolerated, but its longterm safety profile is not yet known.
authors: Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 02111, USA. agottlieb@tuftsmedicalcenter.org
authors: Ari Michael
authors: AM
authors: Goldminz
authors: Alice Bendix
authors: AB
authors: Gottlieb
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D019317:Evidence-Based Medicine; D006801:Humans; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab